Table 2. Comparison of the baseline characteristics between the better and worse survival groups.
| Characteristics | HCC patients with better survival (n = 14) | HCC patients with worse survival (n = 10) | P value |
|---|---|---|---|
| Sex (male) | 13 (92.9) | 8 (80.0) | 0.348 |
| Age, yr | 56.2 ± 11.8 | 58.9 ± 7.9 | 0.472 |
| Etiology | 0.811 | ||
| Alcoholism | 2 (14.3) | 1 (10.0) | |
| CHB | 9 (64.3) | 6 (60.0) | |
| CHC | 2 (14.3) | 1 (10.0) | |
| Combined | 1 (7.1) | 2 (20.0) | |
| Cirrhosis | 11 (78.6) | 9 (90.0) | 0.459 |
| Child-Pugh class | 0.051 | ||
| A | 13 (92.9) | 6 (60.0) | |
| B | 1 (6.7) | 4 (40.0) | |
| Albumin, g/dL | 3.8 ± 0.3 | 3.7 ± 0.4 | 0.438 |
| Total bilirubin, mg/dL | 1.0 ± 0.7 | 1.6 ± 0.8 | 0.056 |
| Prothrombin time, INR | 1.1 ± 0.2 | 1.2 ± 0.1 | 0.625 |
| Baseline high AFP (> 200 ng/mL) | 6 (42.9) | 7 (70.0) | 0.188 |
| Baseline high PIVKA-II (> 125 mAU/mL) | 8 (61.5) | 9 (90.0) | 0.123 |
| MVI | 3 (21.4) | 9 (90.0) | 0.001 |
| Metastasis | 11 (78.6) | 5 (50.0) | 0.143 |
| AJCC staging | 0.143 | ||
| 3 | 3 (21.4) | 5 (50.0) | |
| 4 | 11 (78.6) | 5 (50.0) |
Values are expressed as number (percentage) or median ± standard deviation where specified.
HCC = hepatocellular carcinoma, CHB = chronic hepatitis B, CHC = chronic hepatitis C, AFP = alpha-fetoprotein, INR = international normalized ratio, PIVKA-II = protein induced by vitamin K absence/antagonist-II, MVI = macrovascular invasion, AJCC = American Joint Committee on Cancer.